Strong Development Pipeline

A diverse pipeline designed to address significant unmet medical needs

We are focused on developing a new generation of targeted, empowered therapies with the goal of advancing the foundation of care. In addition to a comprehensive development program to further expand ADCETRIS® (brentuximab vedotin), our robust pipeline is designed to address significant unmet medical needs.

Brentuximab Vedotin

Hodgkin Lymphoma (HL)

Target: CD30

Technology Platform: ADC using MMAE

Collaborator:

ECHELON-1: Frontline HL

sBLA accepted for filing

CHECKMATE 812: Relapsed HL (+ nivolumab, an immunotherapy)

Enrolling

Frontline HL in patients ≥ 60 (± chemotherapy or nivolumab, an immunotherapy)

Enrolling

Second-line HL (+ nivolumab, an immunotherapy)

Enrolling

Non-Hodgkin Lymphoma (NHL)

Target: CD30

Technology Platform: ADC using MMAE

Collaborator:

ECHELON-2: Frontline CD30-expressing mature T-cell lymphoma (also known as PTCL)

Enrollment complete

Relapsed NHL (+ nivolumab, an immunotherapy)

Enrolling

Other Programs

Solid Tumors

Target: Nectin-4

Technology Platform: ADC using MMAE

Collaborator:

Urothelial cancer post-checkpoint inhibitors

Planned

EV201: Urothelial cancer (potentially registrational)

Enrolling

EV103: First-line urothelial cancer (+ checkpoint inhibitor)

Enrolling

Target: Tissue factor

Technology Platform: ADC using MMAE

Collaborator:

Recurrent cervical cancer (potentially registrational)

Planned

First-line cervical cancer (combination)

Planned

Other solid tumors

Planned

Breast Cancer

Target: HER2

HER2CLIMB: HER2-positive breast cancer

Pivotal

Target: LIV-1

Technology Platform: ADC using MMAE

I-SPY 2: HER2-negative breast cancer

Enrolling

Triple negative breast cancer (TNBC) (+ pembrolizumab)

Enrolling

TNBC (+ atezolizumab)


Breast cancer

Enrolling

Lymphoma

Target: CD19

Technology Platform: ADC using MMAF

Diffuse large B-cell lymphoma

Enrolling

Target: CD19

Technology Platform: ADC using PBD

Relapsed/refractory aggressive B-cell NHL

Enrolling

Leukemia

Target: CD123

Technology Platform: ADC using PBD

Relapsed/refractory acute myeloid leukemia

Enrolling

Multiple Myeloma

Target: CD352

Technology Platform: ADC using PBD

Relapsed/refractory multiple myeloma

Enrolling

Target: CD48

Technology Platform: ADC using MMAE

Relapsed/refractory multiple myeloma

Enrolling

Immuno-Oncology

Technology Platform: sugar engineered antibody targeting CD40, an immune-activating receptor capable of driving an antitumor response

Advanced cancer (+/- checkpoint inhibitor)

Enrolling

Technology Platform: An oral immuno-oncology agent that inhibits fucosylation

Advanced solid tumors

Enrolling

ACTR-BCMA

Technology Platform: Novel antibody-coupled T-cell receptor (ACTR) therapy

Collaborator:

Multiple myeloma

Enrolling